Abstract
Background: Idiopathic full-thickness macular holes (FTMH) are an important cause of loss of central vision in the elderly. Improved understanding of the natural history and pathophysiology of FTMH has led to recent advances in the surgical management of patients with this hitherto untreatable condition.
Methods: The current concepts of the natural history and surgical treatment are reviewed. Pilot studies of vitrectomy undertaken to relieve the tangential traction at the vitreomacular interface and the role of growth factors as promoters of a limited healing response are reviewed and illustrated by the results of surgical treatment of macular holes obtained by the author and others.
Results: Whereas early pilot studies of vitrectomy of impending (stage I) macular hole suggested beneficial results (80–95% of operated eyes did not progress to FTMH), no such benefit could be demonstrated by a subsequent randomised treatment trial. In a study of early vitrectomy and partial fluid-gas exchange hole closure was achieved in 88% of patients with stage II FTMH with visual improvement in 67%. In other studies of FTMH (stages II–IV) the addition of adjunctive substances such as growth factors, autologous serum, plasma or platelet concentrate has resulted in closure in 77–100% of cases. However, similar results have also been reported with vitrectomy and gas tamponade alone. Histologically the closure of the FTMH is associated with glial proliferation.
Conclusion: Vitrectomy and intraocular tamponade appear to be beneficial in patients with FTMH. The role of adjunctive substances, such as growth factors and other promoters of the healing response, requires clarification by randomised treatment trials.
Similar content being viewed by others
Article PDF
References
Aaberg TM, Blair CJ, Gass JDM . Macular holes. Am J Ophthalmol 1970;69:555–62.
James M, Feman SS . Macular holes. Graefes Arch Clin Exp Ophthalmol 1980;215:59–63.
The Eye Disease Case-Control Study Group. Risk factors for idiopathic macular holes. Am J Ophthalmol 1994;118:754–61.
Trempe CL, Weiter JJ, Furukawa H . Fellow eyes in cases of macular hole: biomicroscopic study of the vitreous. Arch Ophthalmol 1986;104:93–5.
Hikichi T, Akiba J, Trempe CL . Effect of the vitreous on the prognosis of full-thickness idiopathic macular holes. Am J Ophthalmol 1993;116:273–8.
Gass JDM . Idiopathic senile macular hole: its early stages and pathogenesis. Arch Ophthalmol 1988;106:629–39.
de Bustros S . Vitrectomy for prevention of macular holes: results of a randomised multicentre clinical trial. Ophthalmology 1994;101:1055–9.
Akiba J, Yoshida A, Trempe CL . Risk of developing a macular hole. Arch Ophthalmol 1990;108:1088–90.
Fisher YL, Slakter JS, Yannuzzi LA, Guymer DR . A prospective natural history study and kinetic ultrasound evaluation of idiopathic macular holes. Ophthalmology 1994;101:5–11.
Smiddy WE, Michels RG, Glaser BM, de Bustros S . Vitrectomy for impending idiopathic macular holes. Am J Ophthalmol 1988;105:371–6.
Jost BF, Hutton WL, Fuller DG, Vaiser A, Snyder WB, Fish GE, et al. Vitrectomy in eyes at risk for macular hole formation. Ophthalmology 1990;97:843–7.
Orr GM, Gregor ZJ . Surgery for impending macular holes. Unpublished data presented at the 1993 Congress of the Royal College of Ophthalmologists.
Kelly NE, Wendel RT . Vitreous surgery for idiopathic macular holes: results of a pilot study. Arch Ophthalmol 1991;109:654–9.
Glaser BM, Michels RG, Kuppermann BD, Sjaarda RN, Pena RA . Transforming growth factor beta-2 for the treatment of full-thickness macular holes. Ophthalmology 1992;99:1162–73.
Liggett PE, Skolik SA, Horio B, Saito Y, Alfrao DV, Mieler WF . Human autologous serum for the treatment of full-thickness macular holes. Ophthalmology 1995;102:1071–6.
Patel AC, Wendel RT . Vitrectomy for macular hole. Semin Ophthalmol 1994;9:47–55.
Ruby AJ, Williams DF, Grand MG, Thomas MA, Meredith TA, Boniuk I, Olk RJ . Pars plana vitrectomy for treatment of Stage 2 macular holes. Arch Ophthalmol 1994;112:359–64.
Gregor ZJ, Orr GM . Vitrectomy and fluid gas exchange for early full-thickness macular holes. Retina Society, 25th Annual Meeting, 1992:107.
Wendel RT, Patel AC, Kelly NE, Salzano TC, Wells JW, Novack GD . Vitreous surgery for macular holes. Ophthalmology 1993;100:1671–6.
Guyer DR, de Bustros S, Diener-West M, Fine SL . Observations on patients with idiopathic macular holes and cysts. Arch Ophthalmol 1992;95:917–24.
Lewis H, Cowan GM, Straatsma BR . Apparent disappearance of a macular hole associated with development of an epiretinal membrane. Am J Ophthalmol 1986;102:172–5.
Guyer DR, Green WR, de Bustros S, Fine SL . Histopathologic features of idiopathic macular holes and cysts. Ophthalmology 1990;97:1045–51.
Ruby AJ, Williams DF, Grand G, Thomas MA, Meredith TA, Boniuk I, Olk J . Pars plana vitrectomy for treatment of Stage 2 macular holes. Arch Ophthalmol 1994;112:359–64.
Smiddy WE, Glaser BM, Green R, Connor TB, Roberts AB, Lucas R, Sporn MB . Transforming growth factor beta: a biologic chorioretinal glue. Arch Ophthalmol 1989;107:577–80.
Lansing MB, Glaser BM, Liss H, Hanham A, Thompson JT, Sjaarda RN, Gordon AJ . The effect of pars plana vitrectomy and transforming growth factor beta-2 without epiretinal membrane peeling on full-thickness macular holes. Ophthalmology 1993;100:868–72.
Thompson JT, Smiddy WE, Williams GA, Sjaarda RN, Flynn HW, Margherio RR, et al. Comparison of recombinant TGF-β2 and placebo at three months in the treatment of macular holes. The Macular Society, 18th Annual Meeting 1995:110.
Christmas NJ, Skolik SA, Howard MA, Saito Y, Barnstable CJ, Liggett PE . Treatment of retinal breaks with autologous serum in an experimental model. Ophthalmology 1995;102:263–71.
Wells JA, Gregor ZJ . Surgical treatment of macular holes using autologous serum. Eye 1996;10:593–9.
Garcia-Arumi J, Corcostegui B, Mateo C, Adan A, Salvador F . Surgical management of idiopathic macular holes by vitrectomy and autologous serum. Communication to Club Jules Gonin, Versailles, September 1994.
Hitaizumi Y, Transfeldt EE, Kawahara N, Sung JH, Knighton D, Fiegel VD . In vitro angiogenesis by platelet-derived wound-healing formula in injured spinal cord. Brain Res Bull 1993;30:353–7.
Ksander GA, Sawamura S, Ohawa Y, Sundsmo J, McPherson J . The effect of platelet release on wound healing in animal models. J Am Acad Dermatol 1990;22:781–91.
Gaudric A, Massin P, Paques M, Santiago PY, Guez JE, La Gargasson JF, et al. Autologous platelet concentrate for the treatment of full-thickness macular holes. Graefes Arch Clin Exp Ophthalmol 1995;233:549–54.
Blumenkranz MS, Coll GE, Chang S, Morse LS . Use of autologous plasma-thrombin mixture as adjuvant therapy for macular hole. Ophthalmology 1994;101(Suppl):769.
Tilanus M, Deutman AF . Treatment of macular holes with Tissucol. Communication to Club Jules Gonin, Versailles, September 1994.
Iwasaki T, Sanada A, Yamamoto K, Okade A, Usui NM . The use of fibrin tissue adhesive in the treatment of macular holes. Invest Ophthalmol Vis Sci 1995;36:1050.
Funata M, Wendel RT, de la Cruz Z, Green WR . Clinicopathologic study of bilateral macular holes treated with pars plana vitrectomy and gas tamponade. Retina 1992;12:289–98.
Madraperla SA, Geiger GL, Funata M, de la Cruz Z, Green R . Clinicopathologic correlation of a macular hole treated by cortical vitreous peeling and gas tamponade. Ophthalmology 1994;11:611–3.
Author information
Authors and Affiliations
Additional information
Presented in part at the Vitreous Symposium, Annual Congress of the Royal College of Ophthalmologists, 1995.
Rights and permissions
About this article
Cite this article
Gregor, Z. Surgery for idiopathic full-thickness macular holes. Eye 10, 685–690 (1996). https://doi.org/10.1038/eye.1996.161
Issue Date:
DOI: https://doi.org/10.1038/eye.1996.161